{'fraction_non_alphanumeric': 0.034782608695652174, 'fraction_numerical': 0.004968944099378882, 'mean_word_length': 5.830508474576271, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].

May-Hegglin anomaly (MHA) is the prototype of autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies/MYH9 disorders that result from mutations in MYH9, the gene for nonmuscle myosin heavy chain-IIA (NMMHC-IIA). Others include Sebastian, Fechtner, and Epstein syndromes. A clear phenotype-genotype relationship has not been found; however, patients with an MYH9 head domain mutation tend to develop Alport manifestations more frequently than those with a rod domain mutation. Patients initially diagnosed with MHA and/or Sebastian syndrome can subsequently develop nephritis, deafness, and/or cataracts. Thus, the development of Alport manifestations should be monitored by careful follow-up.